

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gębicki *et al.*

Appl. No. 10/585,892;
§ 371 Date: July 11, 2006

U.S. Nat'l Stage of PCT/EP05/50057;
I.A. Fd: January 7, 2005

For: Use of Quaternary Pyridinium Salts
as Vasoprotective Agents

Confirmation No. 7625

Art Unit: 1614

Examiner: Nelson Clarence Blakely III

Atty. Docket: 2782.0010001/MAC

Reply To Second Restriction Requirement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Madam Commissioner:

Reply to the Restriction Requirement

In reply to the Restriction Requirement dated January 29, 2009, Applicants hereby provisionally elect to prosecute the invention of **Group I**, represented by claims 57-64, 70-72, 74-80 and 86 (and by new claims 87-89, added by amendment herewith). This election is made without prejudice to or disclaimer of the other claims or inventions disclosed. This restriction of Groups I and II is made without traverse.

Reply to the Election of Species

In reply to the election of species requirement, Applicants elect the species of claim 63, i.e., the condition or disease of hypertriglyceridemia.